Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Five Under 5: Top Oncology Videos for the Week of 7/6

July 13th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

The OncFive: Top Oncology Articles for the Week of 7/6

July 12th 2025

The FDA approves Y-90 resin microspheres in HCC, the sNDA for decitabine/cedazuridine plus venetoclax in AML is under review, and more.

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML

July 9th 2025

Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

mFOLFIRINOX Does Not Significantly Improve Survival Vs mFOLFOX6 in HER2– Metastatic Gastric/GEJ Adenocarcinoma

July 6th 2025

IRIGA trial comparing mFOLFIRINOX vs mFOLFOX6 shows mixed results in HER2-negative metastatic gastric and GEJ adenocarcinoma.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

RATIONALE-306 Subgroup Data Further Support First-line Tislelizumab/Chemo in Locally Advanced ESCC

July 5th 2025

Tislelizumab plus chemotherapy improves efficacy vs chemotherapy alone in locally advanced ESCC, including those with PD-L1 TAP of 5% or higher.

The OncFive: Top Oncology Articles for the Week of 6/29

July 5th 2025

The FDA grants approval to sunvozertinib in NSCLC and linvoseltamab in myeloma and removes REMS requirements for approved CAR T-cell therapies.

Trifluridine/Tipiracil Numerically Improves DFS After Curative Resection in ctDNA+ CRC

July 5th 2025

Treatment with trifluridine/tipiracil led to an improvement in disease-free survival in ctDNA-positive colorectal cancer after curative resection.

ctDNA-Guided Surveillance Leads to Increased Curative-Intent Treatment After Recurrence in Nonmetastatic CRC

July 5th 2025

ctDNA monitoring led to earlier recurrence detection and increased use of curative-intent treatment after recurrence in nonmetastatic colorectal cancer.

Real-World Analysis Sheds Light on Fruquintinib Use in Later-Line Metastatic CRC

July 4th 2025

A real-world study in Portugal showed fruquintinib displayed a manageable safety profile and an efficacy trend in refractory colorectal cancer.

Nivolumab/Ipilimumab Maintains OS, ORR Benefits in Chinese Patients With Unresectable HCC

July 4th 2025

Nivolumab plus ipilimumab maintained an ORR benefit across subgroups of Chinese patients with unresectable hepatocellular carcinoma.

Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC

July 4th 2025

Post hoc analyses compared encorafenib plus cetuximab and mFOLFOX6 with different BREAKWATER control arm regimens.

Fruquintinib Demonstrates Clinical Benefit in mCRC Irrespective of Metastatic Sites at Baseline

July 4th 2025

A post hoc subgroup analysis of FRESCO-2 shed light on the safety and efficacy of fruquintinib by metastatic site in metastatic colorectal cancer.

On-Demand TACE Plus Atezolizumab/Bevacizumab Boosts PFS in Unresectable HCC

July 3rd 2025

TACE plus atezolizumab and bevacizumab may represent effective option for untreated intermediate-to-high tumor burden unresectable HCC.

TTFields Plus Chemo Improves QOL, Delays Time to Pain Deterioration in Locally Advanced Pancreatic Adenocarcinoma

July 3rd 2025

The addition of TTFields to chemotherapy improved quality of life and delayed time to pain deterioration in locally advanced pancreatic cancer.

Nivolumab Plus Ipilimumab Improves HRQOL Vs Nivolumab Alone in MSI-H/dMMR mCRC

July 3rd 2025

CheckMate 8HW data show ipilimumab plus nivolumab improved PFS vs nivolumab alone while maintaining HRQOL.

Perioperative Durvalumab/FLOT Does Not Diminish PROs in Resectable Gastric/GEJ Adenocarcinoma

July 3rd 2025

Durvalumab plus FLOT did not lead to differences in patient-reported outcomes vs placebo plus FLOT in resectable gastric/GEJ cancer.

Givastomig Combo Shows Early Promise in CLDN18.2+ Gastric, Esophageal, GEJ Adenocarcinoma

July 2nd 2025

Givastomig paired with chemoimmunotherapy was tolerable and elicited responses in CLDN18.2+ gastric, esophageal, and GEJ cancers.

Dr Bazhenova on the FDA Approval of Sunvozertinib for EGFR-Mutated mNSCLC

July 2nd 2025

Lyudmila A. Bazhenova, MD, discusses ways that sunvozertinib expands the treatment paradigm for EGFR-mutated metastatic non–small cell lung cancer.

FDA Grants Accelerated Approval to Sunvozertinib for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

July 2nd 2025

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy) for locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.